# DESCRIPTION

## FIELD OF INVENTION

- relate to predicting in vivo toxicity of oligonucleotides

## BACKGROUND

- recognize promise of antisense oligonucleotides
- describe complexity of oligonucleotide development
- highlight unpredictability of toxicity
- discuss limitations of in vitro toxicity assays
- introduce bioinformatics approaches to predict toxicity
- mention need for predictive assays

## SUMMARY OF THE INVENTION

- provide in vitro toxicity assays
- use primary mammalian hepatocytes
- identify molecular markers of toxicity
- correlate with in vivo toxicity profile
- provide effective in vitro assay
- describe method for predicting in vivo toxicity
- administer oligonucleotide to hepatocytes
- culture cells in vitro
- measure biomarkers of toxicity
- provide method for determining in vivo toxicity
- select oligonucleotides for in vivo administration
- obtain library of oligonucleotides
- administer each oligonucleotide to hepatocytes
- culture cells in vitro
- measure biomarkers of toxicity
- select oligonucleotides with low toxicity
- optionally administer selected oligonucleotide in vivo
- describe gymnosis administration
- compare biomarker levels to control data
- use LDH release as biomarker
- use ATP levels as biomarker
- use microRNA-122 as biomarker
- use cytokines as biomarkers
- use glutathione levels as biomarker
- provide various embodiments of biomarkers

## DETAILED DESCRIPTION OF THE INVENTION

### Prediction of In Vivo Toxicity

- predict in vivo toxicity of oligonucleotide
- assess comparative toxicity profile
- identify non-toxic oligonucleotides
- select oligonucleotides with wide safety margin
- calculate therapeutic index

### Primary Mammalian Hepatocyte Cells

- introduce primary mammalian hepatocyte cells
- describe liver perfusion methods
- select primary hepatocyte cells
- use cryopreserved primary hepatocytes
- use iPS cells-derived hepatocytes
- describe monoculture and co-culture
- identify predictive biomarkers
- use ATP, LDH, and microRNA-122 biomarkers
- use cytokine release in co-culture
- use intracellular GSH biomarker
- describe non-parenchymal cells

### Administering the Oligonucleotide—Gymnotic Delivery (Gymnosis)

- administer oligonucleotide to primary hepatocytes
- describe gymnotic delivery
- use concentration of oligonucleotide
- describe culturing step
- use short culturing period
- describe cell culture conditions
- define about
- measure LDH and ATP levels
- compare to reference value
- describe caspase signal
- describe advantages of gymnotic delivery

### Control Data/Reference Values

- describe control data
- compare to negative control
- compare to positive control
- describe alteration of biomarker
- describe decrease of cellular ATP
- describe elevation of LDH
- describe control data from library of oligonucleotides

### (Determination of) Hepatotoxicity

- define hepatotoxicity
- introduce liver toxicity biomarkers
- describe in vivo oligonucleotide hepatotoxicity determination
- introduce screening library of variants
- outline method for selecting oligonucleotides with reduced toxicity
- describe administration of oligonucleotides to primary mammalian hepatocyte cells
- outline culturing of cells and measuring biomarkers of toxicity
- select oligonucleotides with reduced toxicity
- optionally administer selected oligonucleotides in vivo
- describe library of oligonucleotides with different nucleobase sequences
- describe library of oligonucleotide variants of a parent oligonucleotide
- outline stereodefined phosphorothioate internucleoside linkages
- describe antisense oligonucleotide
- describe LNA oligonucleotide
- outline library of child oligonucleotides with different gapmer designs
- describe stereodefined oligonucleotides with reduced in vivo toxicity
- outline method for reducing toxicity of phosphorothioate oligonucleotide
- describe creating library of stereodefined phosphorothioate oligonucleotides
- outline screening library and identifying reduced toxicity oligonucleotides
- describe manufacturing stereodefined phosphorothioate oligonucleotides

### Parent Oligonucleotide

- describe non-stereodefined phosphorothioate oligonucleotide
- outline parent oligonucleotide with stereodefined phosphorothioate internucleoside linkages

### Library of Variants

- create library of variants of parent oligonucleotide
- describe each member of library with stereodefined phosphorothioate internucleoside linkages
- outline at least 2 stereodefined phosphorothioate linkages
- describe all phosphorothioate linkages as stereodefined
- outline all internucleoside linkages as stereodefined phosphorothioate linkages
- create library by inserting stereodefined phosphorothioate internucleoside linkages
- describe inserting stereodefined phosphorothioate internucleoside linkages into gap-region
- describe inserting stereodefined phosphorothioate internucleoside linkages into wing-regions
- describe inserting stereodefined phosphorothioate internucleoside linkages into gap-region and wing-regions
- outline remaining internucleoside linkages as same as parent
- describe child oligonucleotides with 1-20 independently stereodefined phosphorothioate internucleoside linkages
- outline all phosphorothioate internucleoside linkages as stereodefined
- describe all internucleoside linkages as stereodefined phosphorothioate linkages
- outline each member of library with at least 2 stereodefined phosphorothioate linkages
- describe all phosphorothioate linkages as stereodefined
- outline all internucleoside linkages as stereodefined phosphorothioate linkages
- describe retaining pattern of modified and unmodified nucleosides

### Stereodefined Oligonucleotide Embodiments:

- define stereodefined oligonucleotide method
- specify parent oligonucleotide type
- create library of stereodefined oligonucleotide variants
- screen library for in vitro toxicity
- identify stereodefined variants with reduced toxicity
- specify stereodefined phosphorothioate linkages
- retain pattern of modified and unmodified nucleosides
- determine in vitro or in vivo potency

### Primary Hepatocytes Assay Example:

- describe cell culture conditions
- specify cell seeding and treatment protocol
- detail cell culture medium composition
- provide example cell culture parameters

## Definitions

### Oligonucleotide

- define oligonucleotide
- describe structure
- specify length
- describe modifications
- specify nucleotide sequence
- describe synthesis and purification
- specify applications
- describe types of oligonucleotides

### Antisense Oligonucleotides (ASOs)

- define antisense oligonucleotides
- describe function
- specify types of ASOs
- describe applications

### Modified Internucleoside Linkages

- describe modified linkages
- specify phosphorothioate linkages
- describe other modified linkages
- specify neutral internucleoside linkages
- describe additional linkages
- specify nuclease resistant linkages
- describe inclusion of phosphodiester linkages

### Modulation of Expression

- define modulation of expression
- describe inhibition of expression
- describe restoration of expression
- describe determination of target modulation

### Modified Oligonucleotides

- introduce modified oligonucleotides
- motivate phosphorothioate internucleoside linkages
- describe phosphorothioate internucleoside linkages
- introduce high affinity modified nucleosides
- define high affinity modified nucleosides
- describe effect of high affinity modified nucleosides
- provide examples of high affinity modified nucleosides
- introduce sugar modifications
- describe sugar modifications
- provide examples of sugar modified nucleosides
- introduce 2' modified nucleosides
- define 2' modified nucleosides
- describe effect of 2' modified nucleosides
- provide examples of 2' modified nucleosides
- introduce locked nucleic acid nucleosides
- describe locked nucleic acid nucleosides
- provide structural formula for locked nucleic acid nucleosides
- define modified oligonucleotides
- specify biradical structures
- specify LNA unit structures
- define R1*, R2, R3, R5, R5* groups
- specify R1*, R2, R3 groups
- specify R5 and R5* groups
- provide examples of R5 and R5* groups
- define nucleobase B
- provide examples of nucleobase B
- define modified oligonucleotides
- list biradical structures for R4* and R2*
- specify biradical C(RaRb)—N(Rc)—O—
- specify biradical C(RaRb)—O—C(RcRd)—O—
- specify biradical —CH(Z)—O—
- describe bicyclic nucleotides
- specify biradical —CH2—N(Rc)—
- specify biradical -Cq3q4-NOR—
- describe bicyclic nucleotides
- specify biradical C(RaRb)—O—
- specify biradical -Q-
- describe bicyclic nucleotides
- list references for further bicyclic nucleoside analogues
- define LNA structure
- specify Y in LNA structure
- specify Z and Z* in LNA structure
- specify B in LNA structure
- specify RH in LNA structure
- specify Ra, Rb, Rc, Rd, and Re in LNA structure
- describe stereochemical isomers of LNA
- define thio-LNA
- specify configurations of thio-LNA
- define modified oligonucleotides
- introduce amino-LNA
- introduce oxy-LNA
- introduce ENA
- present LNA nucleosides
- define gapmer
- describe gapmer designs
- introduce headmers and tailmers
- describe gapmer oligonucleotides
- specify gap region
- specify flanking regions
- describe LNA gapmer oligonucleotides
- specify monomers capable of recruiting RNAse
- describe gapmer designs with LNA units
- specify region X'
- specify region Y'
- specify region Z'
- describe further gapmer designs
- introduce shortmer gapmers
- describe oligomer designs
- specify nucleotide sequences
- introduce stereodefined gapmers
- define modified oligonucleotides
- describe gapmer oligonucleotide structure
- specify central region characteristics
- detail wing region composition
- introduce stereodefined internucleoside linkages
- describe biological profile modulation
- specify stereoselective phosphorothioate linkages
- define LNA gapmer
- describe LNA gapmer design
- introduce mixed wing gapmer
- describe mixed wing gapmer design
- define gapbreaker oligonucleotide
- describe gapbreaker oligonucleotide structure
- specify gapbreaker nucleoside characteristics
- provide gapbreaker oligonucleotide formulae
- describe optional nucleosides in gapbreaker oligonucleotide
- specify gapbreaker nucleoside types

### RNase H Activity and Recruitment

- define RNase H activity

### Efficacy

- motivate efficacy testing
- describe efficacy determination methods
- specify efficacy criteria
- discuss therapeutic index calculation
- provide potency retention examples
- describe EC50 value evaluation

### Conjugate Moieties

- list carbohydrate conjugate moieties
- list protein and lipid conjugate moieties
- list small molecule and polymer conjugate moieties

### Stereodefined Oligonucleotides

- define stereodefined oligonucleotides
- describe stereodefined phosphorothioate linkages
- discuss stereoselectivity and stereospecificity

## Immunotoxicity Biomarker Assay:

- describe method for predicting immunotoxicity of oligonucleotides
- outline steps of method
- specify biomarkers measured

## EXAMPLES

### Example 1

- describe mouse liver perfusion and hepatocyte isolation
- outline collagenase liver perfusion procedure
- describe hepatocyte culturing and oligonucleotide treatment
- specify cell culture conditions
- describe co-culture method
- outline RNA isolation and qPCR procedure
- describe LDH, albumin, GSH, and ATP assays
- outline apoptosis assay
- describe cytokine measurement
- outline miRNA analysis
- specify cell types used
- describe alternative cell types
- outline use of iPS cells
- specify RNA isolation kit used
- describe cDNA synthesis and qRT-PCR
- outline LDH assay
- describe albumin secretion assay
- outline GSH and ATP assays

### Example 2

- describe evaluation and validation of in vitro hepatotoxicity assays

### Example 3

- describe effect of oligonucleotides on hepatocyte function and viability
- outline LDH and albumin secretion assays
- describe GSH and ATP assays

### Example 4

- describe ASO-mediated effect on apoptosis

### Example 5

- describe effect of oligonucleotides on hepatocyte-NPC co-cultures

### Example 6

- describe changes in secreted cytokines and miR-122

### Example 7

- describe miR-122 release in hepatocyte-NPC co-cultures

### Example 8

- describe testing of 34 ASOs in in vitro hepatotoxicity assay

### Example 9

- describe protocol for human primary hepatocytes
- outline cytotoxicity readouts
- describe testing of reference ASOs

